DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is an Early Phase 1 trial that is no longer enrolling new patients, is there a follow-up or next-phase study I might be eligible for that uses these same imaging techniques — DCE-MRI or molecular breast imaging — to track how my tumor responds to chemotherapy?
2. 2This trial is specifically for triple-negative breast cancer and uses MBI with a radioactive tracer called Tc99m-sestamibi alongside standard imaging like ultrasound and mammogram — how do these imaging approaches compare in their ability to show whether my tumor is responding to chemo, and is any of this available to me outside of a trial?
3. 3Because this study focuses on measuring tumor response during chemotherapy rather than testing a new drug, would participating in something like this change my actual treatment plan at all, or is it purely observational?
4. 4The trial tracks whether imaging results match what's found when pathologists examine the tumor after treatment — based on what's been learned so far from studies like this, does my care team use DCE-MRI or MBI results to guide my chemotherapy decisions, and should they?
5. 5Triple-negative breast cancer is known to be aggressive, so how do you weigh the time and logistics of additional imaging visits — which a study like this would require — against focusing on moving quickly with standard treatment?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.